{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ramezani-Rad P"],"funding":["NIAID NIH HHS","NIH","NIH HHS"],"pagination":["e185292"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11996878"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["135(8)"],"pubmed_abstract":["Induction of durable protective immune responses is the main goal of prophylactic vaccines, and adjuvants play a role as drivers of such responses. Despite advances in vaccine strategies, development of a safe and effective HIV vaccine remains a significant challenge. Use of an appropriate adjuvant is crucial to the success of HIV vaccines. Here we assessed the saponin/MPLA nanoparticle (SMNP) adjuvant with an HIV envelope (Env) trimer, evaluating the safety and effect of multiple variables - including adjuvant dose (16-fold dose range), immunization route, and adjuvant composition - on the establishment of Env-specific memory T and B cell (TMem and BMem) responses and long-lived plasma cells in nonhuman primates (NHPs). Robust BMem were detected in all groups, but a 6-fold increase was ob"],"journal":["The Journal of clinical investigation"],"pubmed_title":["The saponin monophosphoryl lipid A nanoparticle adjuvant induces dose-dependent HIV vaccine responses in nonhuman primates."],"pmcid":["PMC11996878"],"funding_grant_id":["S10OD025052","UM1AI144462","S10 OD025052","UM1 AI144462","U24 AI126683","51OD011107","P51 OD011107"],"pubmed_authors":["Marina-Zarate E","Irvine DJ","Sagar SL","Myers A","Ramezani-Rad P","Maiorino L","Sayeed E","Burton DR","Crotty S","Lemnios AA","Budai M","Burton I","Pires IS","Wagner A","Schief WR","Cottrell CA","Pradhan A","Kasturi SP","Groschel B","Van Rompay KK","Melo MB","Lopez PG","Hangartner L","Kaczmarek Michaels K","Kumar D","Stiegler G","Pallerla S","Bloom NI"],"additional_accession":[]},"is_claimable":false,"name":"The saponin monophosphoryl lipid A nanoparticle adjuvant induces dose-dependent HIV vaccine responses in nonhuman primates.","description":"Induction of durable protective immune responses is the main goal of prophylactic vaccines, and adjuvants play a role as drivers of such responses. Despite advances in vaccine strategies, development of a safe and effective HIV vaccine remains a significant challenge. Use of an appropriate adjuvant is crucial to the success of HIV vaccines. Here we assessed the saponin/MPLA nanoparticle (SMNP) adjuvant with an HIV envelope (Env) trimer, evaluating the safety and effect of multiple variables - including adjuvant dose (16-fold dose range), immunization route, and adjuvant composition - on the establishment of Env-specific memory T and B cell (TMem and BMem) responses and long-lived plasma cells in nonhuman primates (NHPs). Robust BMem were detected in all groups, but a 6-fold increase was ob","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-01T14:53:49.946Z","creation":"2026-04-08T13:33:56.438Z"},"accession":"S-EPMC11996878","cross_references":{"pubmed":["40036068"],"doi":["10.1172/JCI185292"]}}